2025 Winter Clinical™ Miami Highlights

Our Annual Winter Clinical™ Miami conference is framed to improve our attendees' value and clinical skills through a uniquely designed educational experience. Check back here as we highlight key sessions and posters during the conference!

Friday, January 17, 2025

Check Out Highlights From WCM25 Below

Contact Dermatitis Update for 2025

Kicking off the first day of lectures in Miami, David Cohen, MD, MPH, provided an insightful overview of contact dermatitis, focusing on allergens dermatologists should monitor in 2025....

What's New in the Treatment of Non-Scarring Alopecia

In this presentation, Amy McMichael MD, discussed the latest updates in the treatment of common types of non-scarring alopecia, including pattern hair loss and alopecia areata (AA). She...

Topical & Systemic Antibiotic Therapy

Antimicrobial resistance (AMR) has become one of the most urgent global health crises, as highlighted by Theodore Rosen, MD, in his impactful session, "Topical and Systemic Antibiotic Therapy."...

What's New Pediatric Infections

Rounding out the first day, Elizabeth Swanson, MD, presented an engaging review of emerging trends and treatments in pediatric infections, offering updates across various dermatologic conditions. She began...

Expert Consensus-Based Recommendations on the Use of Photodynamic Therapy in Actinic Keratosis Patients

Authors: Vishal A. Patel, MD; Sarah T. Arron, MD, Brian Berman, MD, PhD; M. Shane Chapman, MD, MBA; Anokhi Jambusaria-Pahlajani, MD; George Martin, MD; Anthony M. Rossi, MD;...

Pilot Study Utilizing Short Contact Protocols For Treatment Of Actinic Keratoses (AK) With ALA Gel-Red Light Photodynamic Therapy (PDT).

Authors: Jessica Johnson, BS; Jackson Hanna, BS; Amy S. Nowacki, PhD; Edward Maytin, MD, PhD

Photodynamic therapy (PDT) combines the photosensitizer 5-aminolevulinic acid (ALA) with an artificial light...

Therapeutic Update

Gary Goldenberg, MD, opened day 2 with an extensive review of the latest research on a broad range of dermatologic conditions, including acne vulgaris, psoriasis, atopic dermatitis (AD),...

Psoriasis Tips

Mark Lebwohl, MD, addressed a common clinical dilemma: selecting appropriate treatment regimens for patients with psoriasis amidst an expanding array of biologics and small-molecule inhibitors. His presentation emphasized...

Say ‘No’ to Spontaneity: Treating Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) is defined by recurring hives, swelling, or both, and lasting 6 weeks or more, without identifiable triggers such as allergies or external stimuli. Dawn...

Gene Expression Profiling of Skin Cancer: Transforming Diagnosis and Prognosis

Gene expression profiling (GEP) is revolutionizing the management of skin cancers by enhancing diagnostic precision and prognostic accuracy. Darrell Rigel, MD, MS, and Aaron Farberg, MD, emphasized the...

Clinical Pearls Panel

Rounding out the second day was a multispeaker session on clinical pearls by Gary Goldenberg, MD, Brad Glick, DO, Edward (Ted) Lain, MD, MBA, Elizabeth (Lisa) Swanson, MD,...

Botulinum Toxin Update

Mark Nestor, MD, PhD, provided an in-depth update on the science of botulinum toxin type A (BoNT-A), focusing on how to select the right toxin and optimize clinical...

Choosing the Right Systemic Treatment for Your Patients with Atopic Dermatitis

While many systemic treatments are available for atopic dermatitis (AD), Dr Alexandra Golant focused her lecture on the latest advancements and evidence-based strategies for choosing the right therapy....

Alopecia Areata Update

Alopecia areata is a complex autoimmune condition with profound physical and emotional impacts on patients. Natasha Mesinkovska, MD, PhD, opened her presentation with a fascinating discussion on mortality...

Worldwide Clinical and Real-World Exposure to Baricitinib

Authors: Ruth Ann Vleugels, Brittany Craiglow, Arash Mostaghimi, Elise Olsen, Angelina Sontag, Karen Denning, Najwa Somani, Maria Hordinsky

Baricitinib, an oral JAK inhibitor, is approved for conditions such...

Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study

Authors: Andrew Alexis, Ali Moiin, Jill Waibel, Paul Wallace, David Cohen, Vivian Laquer, Pearl Kwong, Amber Reck Atwater, Jennifer Proper, Maria Silk, Evangeline Pierce, Sreekumar Pillai, Maria Jose...

What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 1

Darrell S. Rigel, MD, MS started this multi-part discussion highlighting significant advancements in dermatologic oncology. Key updates include the efficacy of tirbanibulin 1% for treating actinic keratosis (AK)...

What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 2

In Part 2 of “What Did Dermatology Bring to the Table in 2024 that Impact Patient Care in 2025” series, Seemal Desai, MD, Mark Lebwohl, MD, Dawn Merritt,...

What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 3

In this presentation, Gary Goldenberg, MD and Mark Nestor, MD, PhD, provided valuable insights into botulinum toxin (Botox) injections, collagen biostimulators, androgenetic alopecia (AGA) treatments, and innovative aesthetic...

Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From Adjoin

Authors: Emma Guttman-Yassky, Alan Irvine, Eric Simpson, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan Silverberg, Heidi Crane, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Evangeline...

Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From 11 Trials With Over 3000 Patient-Years of Exposure

Authors: Linda Stein Gold, Eric Simpson, Diamant Thaçi, Alan Irvine, Marjolein de Bruin-Weller, Gaia Gallo, Maria Lucia Buziqui Piruzeli, Hany Elmaraghy, Jinglin Zhong, Sonia Montmayeur, Ruth Coll, Mark...